Context Therapeutics to Participate in Upcoming Investor Conferences in November
October 23 2024 - 7:30AM
Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX),
a biopharmaceutical company advancing T cell engagers for solid
tumors, today announced that the Company will participate in the
following investor conferences in November:
- Guggenheim Global Healthcare
Conference: Fireside
chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston,
MA.
- UBS Global Healthcare
Conference: Fireside chat on Wednesday,
November 13, 2024, at 11:45 a.m. PT in Rancho Palos Verdes,
CA.
- Stifel 2024 Healthcare
Conference: Presentation on Tuesday, November 19,
2024 at 1:50 p.m. ET in New York, NY.
Context will also participate in one-on-one meetings at each of
the above conferences.
A live webcast of each presentation will be available on the
News and Events section of the Company’s website at
https://ir.contexttherapeutics.com. Replays will be available on
the website for 90 days.
About Context Therapeutics®Context Therapeutics
Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T
cell engaging (“TCE”) bispecific antibodies for solid tumors.
Context is building an innovative portfolio of TCE bispecific
therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific
antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and
CT-202, a Nectin-4 x CD3 bispecific antibody. Context is
headquartered in Philadelphia. For more information, please
visit www.contexttherapeutics.com or follow the Company
on X (formerly Twitter) and LinkedIn.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,”
“intend,” and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are forward-looking statements. These include,
without limitation, statements regarding (i) the ability of the
Company and its employees to participate in and present at
conferences, (ii) the potential benefits, characteristics, safety
and side effect profile of our product candidates, and (iii) the
likelihood data will support future development. Forward-looking
statements in this release involve substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by the forward-looking statements,
and we therefore cannot assure you that our plans, intentions,
expectations, or strategies will be attained or achieved. Other
factors that may cause actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in our filings with the U.S.
Securities and Exchange Commission, including the section titled
“Risk Factors” contained therein. Except as otherwise required by
law, we disclaim any intention or obligation to update or revise
any forward-looking statements, which speak only as of the date
they were made, whether as a result of new information, future
events, or circumstances or otherwise.
Investor Relations Contact:Jennifer
Minai-AzaryChief Financial OfficerContext Therapeutics
Inc.IR@contexttherapeutics.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Dec 2023 to Dec 2024